Oryn Therapeutics is progressing its next-generation Orynotide™ macrocyclic peptide platform aimed at treating inflammatory and autoimmune diseases through immune reprogramming rather than suppression. The company appointed Guy Rosenthal as CEO and expanded its leadership team with industry veterans including Paul Sekhri as executive chairman and Nina Kjellson as a board director. Oryn’s platform focuses on oral and injectable peptides that target complex biological pathways inaccessible to traditional therapies. This strategic leadership expansion and collaboration with Lilly ExploR&D aim to accelerate development of novel therapies addressing unmet medical needs.
Dimensional Fund Advisors Ltd. has disclosed a 1.41% ownership stake in Advanced Medical Solutions Group PLC, holding 3,110,204 ordinary shares as of June 22, 2026. This disclosure follows regulatory requirements under the Takeover Code, indicating D...
Clariane SE has initiated a pre-stabilisation period for its €333 million perpetual subordinated fixed-rate resettable notes. BNP Paribas, along with other banks, will act as stabilisation managers to support the market price during the period from J...
The global enteric disease testing market is projected to grow from $4.08 billion in 2025 to $5.86 billion by 2035, at a CAGR of 3.7%. Growth is fueled by rising foodborne and waterborne diseases, demand for rapid pathogen detection, and adoption of ...
Vaidas Dominauskas will lead Telia Lietuva's business client team starting July 1, 2026, bringing over 14 years of experience at the company and recent leadership at state-owned Regitra. He replaces Aurimas Žlibinas and will focus on expanding the bu...
Investec Bank plc, acting as joint broker to Gamma Communications Plc, disclosed a public dealing on June 22, 2026, involving the purchase and sale of 128,034 ordinary shares of Gamma Communications. The transactions were conducted at prices ranging ...
